Table S4.
Treatment patterns for all patients with advanced NSCLCa
| Treatment regimen | All patients |
|---|---|
| First-line therapy | (N=175) |
| Platinum combination | 115 (66) |
| Carboplatin, paclitaxel | 45 (26) |
| Cisplatin, pemetrexed | 11 (6) |
| Carboplatin, pemetrexed | 10 (6) |
| Bevacizumab, carboplatin, paclitaxel | 8 (5) |
| Carboplatin, tegafur/gimeracil/oteracilb | 5 (3) |
| Single agent | 16 (9) |
| Docetaxel | 8 (5) |
| Carboplatin | 2 (1) |
| Paclitaxel | 2 (1) |
| Tegafur/gimeracil/oteracil | 2 (1) |
| Bevacizumab | 1 (1) |
| Pemetrexed | 1 (1) |
| EGFR/ALK TKI | 44 (25) |
| Gefitinib | 40 (23) |
| Erlotinib | 2 (1) |
| Crizotinib | 2 (1) |
| Second-line therapy | n=105 |
| Platinum combination | 30 (29) |
| Carboplatin, paclitaxel | 9 (9) |
| Bevacizumab, carboplatin, pemetrexed | 5 (5) |
| Carboplatin, pemetrexed | 3 (3) |
| Carboplatin, tegafur/gimeracil/oteracil | 3 (3) |
| Bevacizumab, carboplatin, paclitaxel | 2 (2) |
| Nonplatinum combination | 2 (2) |
| Bevacizumab, pemetrexed | 1 (1) |
| Gemcitabine, vinorelbine | 1 (1) |
| Single agent | 51 (49) |
| Docetaxel | 29 (28) |
| Pemetrexed | 17 (16) |
| Gemcitabine | 3 (3) |
| Tegafur/gimeracil/oteracil | 2 (2) |
| EGFR/ALK TKI | 22 (21) |
| Erlotinib | 17 (16) |
| Gefitinib | 2 (2) |
| Afatinib | 2 (2) |
| Crizotinib | 1 (1) |
| Third-line therapy | n=54 |
| Platinum combination | 12 (22) |
| Carboplatin, paclitaxel | 4 (7) |
| Carboplatin, pemetrexed | 2 (4) |
| Carboplatin, tegafur/gimeracil/oteracil | 2 (4) |
| Albumin-bound paclitaxel, bevacizumab, carboplatin | 1 (2) |
| Albumin-bound paclitaxel, carboplatin | 1 (2) |
| Nonplatinum combination | 5 (9) |
| Gemcitabine, vinorelbine | 2 (4) |
| Albumin-bound paclitaxel, erlotinib | 1 (2) |
| Albumin-bound paclitaxel, erlotinib, gemcitabine, vinorelbine | 1 (2) |
| Gefitinib, pemetrexed | 1 (2) |
| Single agent | 23 (43) |
| Docetaxel | 8 (15) |
| Pemetrexed | 6 (11) |
| Gemcitabine | 2 (4) |
| Paclitaxel | 1 (2) |
| Vinorelbine | 1 (2) |
| Tegafur/gimeracil/oteracil | 5 (9) |
| EGFR/ALK TKI | 13 (24) |
| Erlotinib | 13 (24) |
Notes: Data are n (%). Percentages may not be additive because of rounding.
a
The top 5 regimens for each category are presented.
b
Oral anticancer drug composed of tegafur, gimeracil, and oteracil potassium at a molar ratio of 1:1:0.4.
Abbreviations: ALK, anaplastic lymphoma kinase; EGFR, epidermal growth factor receptor; NSCLC, non-small cell lung cancer; TKI, tyrosine kinase inhibitor.